- patent of invention
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/10/26 07:19:54」(JST)[Wiki ja表示]
- 1 概要
- 2 特許制度の歴史
- 3 特許制度の意義
- 3.1 基本権（自然権）説
- 3.2 産業政策説
- 4 各国の特許制度
- 5 検索サービス
- 6 パテントマップ
- 7 脚注・出典
- 8 関連項目
- 9 外部リンク
1623年にイギリス議会で制定された専売条例（Statute of Monopolies）は、それまで国王が恣意的に認めてきた特許を制限し、発明と新規事業のみを対象として、一定期間（最長14年間）に限って独占権を認めるとともに、権利侵害に対する救済として損害賠償請求を規定した。この条例の制定によって、近代的な特許制度の基本的な考え方が確立されたとされる。また、この条例は、ジェームズ・ワットの蒸気機関（1769年）や、リチャード・アークライトの水車紡績機（1771年）等の画期的な発明がなされる環境を整え、英国に産業革命をもたらしたと評価されている。
パテントマップとは、特許に関する情報を整理・分析・加工して図面、グラフ、表などで表したもので、特許マップ、又は特許地図とも呼ばれている。 パテントマップを見ることで、特許をマクロな視点から把握することができる。 大企業同士の特許係争ともなると出願全件の侵害・非侵害を調べることが現実的ではない場合もあり、交渉の材料としてパテントマップが用いられることもある。 パテントマップの作成業者は、特許庁ホームページ上特許情報提供事業者リスト集から調べることができる。
- ^ 国家（または君主）が法人または個人に対して特権を付与する特許状（英: charter, チャーター）とは意味が異なる。パテントとチャーターの意味の違いに注意
- 特許・実用新案とは 特許庁ホームページ
Inventive step and
|By region / country|
|By specific subject matter|
A patent (// or //) is a set of exclusive rights granted by a sovereign state to an inventor or their assignee for a limited period of time, in exchange for the public disclosure of the invention. An invention is a solution to a specific technological problem, and may be a product or a process.:17 Patents are a form of intellectual property.
The procedure for granting patents, requirements placed on the patentee, and the extent of the exclusive rights vary widely between countries according to national laws and international agreements. Typically, however, a patent application must include one or more claims that define the invention. These claims must meet relevant patentability requirements, such as novelty and non-obviousness. The exclusive right granted to a patentee in most countries is the right to prevent others from making, using, selling, or distributing the patented invention without permission.
Under the World Trade Organization's (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights, patents should be available in WTO member states for any invention, in all fields of technology, and the term of protection available should be a minimum of twenty years. Nevertheless, there are variations on what is patentable subject matter from country to country.
- 1 Definition
- 2 History
- 3 Law
- 3.1 Effects
- 3.2 Enforcement
- 3.3 Ownership
- 3.4 Governing laws
- 3.5 Application and prosecution
- 3.5.1 Costs
- 3.6 Alternatives to applying for a patent
- 4 Economics
- 4.1 Rationale
- 4.2 Criticism
- 4.2.1 Proposed alternatives to the patent system
- 5 See also
- 6 References
- 7 External links
The word patent originates from the Latin patere, which means "to lay open" (i.e., to make available for public inspection). More directly, it is a shortened version of the term letters patent, which was a royal decree granting exclusive rights to a person, predating the modern patent system. Similar grants included land patents, which were land grants by early state governments in the USA, and printing patents, a precursor of modern copyright.
In modern usage, the term patent usually refers to the right granted to anyone who invents any new, useful, and non-obvious process, machine, article of manufacture, or composition of matter. Some other types of intellectual property rights are also called patents in some jurisdictions: industrial design rights are called design patents in the US, plant breeders' rights are sometimes called plant patents, and utility models and Gebrauchsmuster are sometimes called petty patents or innovation patents.
The additional qualification utility patent is sometimes used (primarily in the US) to distinguish the primary meaning from these other types of patents. Particular species of patents for inventions include biological patents, business method patents, chemical patents and software patents.
In 500 BC, in the Greek city of Sybaris (in what is now southern Italy), "Encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year."
The Florentine architect Filippo Brunelleschi received a three-year patent for a barge with hoisting gear, that carried marble along the Arno River in 1421. In 1449, King Henry VI granted the first English patent with a license of 20 years to John of Utynam for introducing the making of colored glass to England.
Patents in the modern sense originated in 1474, when the Republic of Venice enacted a decree that new and inventive devices, once put into practice, had to be communicated to the Republic to obtain the right to prevent others from using them.
England followed with the Statute of Monopolies in 1624, under King James I, which declared that patents could only be granted for "...projects of new invention." During the reign of Queen Anne (1702–14), lawyers of the English Court developed the requirement that a written description of the invention must be submitted. The patent systems in many other countries, including Australia, are based on British law and can be traced back to the Statute of Monopolies.
In 1641, Samuel Winslow was granted the first patent in North America by the Massachusetts General Court for a new process for making salt.
In France, patents were granted by the monarchy and by other institutions like the "Maison du Roi". The Academy examined novelty. Examinations were generally done in secret with no requirement to publish a description of the invention. Actual use of the invention was deemed adequate disclosure to the public. The modern French patent system was created during the Revolution in 1791. Patents were granted without examination since inventor's right was considered as a natural one
In the United States, during the colonial period and Articles of Confederation years (1778–89), several states adopted their own patent systems. The U.S. Constitution authorizes the American patent system in Article One, Section 8(8) which states:
- The Congress shall have power...To promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries...
The first Congress adopted a Patent Act in 1790, and the first patent was issued under this Act on July 31, 1790 (to Samuel Hopkins of Vermont for a potash production technique).
|Intellectual property law|
|Sui generis rights|
A patent does not give a right to make or use or sell an invention. Rather, a patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, which is usually 20 years from the filing date subject to the payment of maintenance fees. A patent is a limited property right the government gives inventors in exchange for their agreement to share details of their inventions with the public. Like any other property right, it may be sold, licensed, mortgaged, assigned or transferred, given away, or simply abandoned.
A patent, being an exclusionary right, does not necessarily give the patent owner the right to exploit the patent. For example, many inventions are improvements of prior inventions that may still be covered by someone else's patent. If an inventor obtains a patent on improvements to an existing invention which is still under patent, they can only legally use the improved invention if the patent holder of the original invention gives permission, which they may refuse.
Some countries have "working provisions" that require the invention be exploited in the jurisdiction it covers. Consequences of not working an invention vary from one country to another, ranging from revocation of the patent rights to the awarding of a compulsory license awarded by the courts to a party wishing to exploit a patented invention. The patentee has the opportunity to challenge the revocation or license, but is usually required to provide evidence that the reasonable requirements of the public have been met by the working of invention.
Patents can generally only be enforced through civil lawsuits (for example, for a U.S. patent, by an action for patent infringement in a United States federal court), although some countries (such as France and Austria) have criminal penalties for wanton infringement. Typically, the patent owner seeks monetary compensation for past infringement, and seeks an injunction that prohibits the defendant from engaging in future acts of infringement. To prove infringement, the patent owner must establish that the accused infringer practises all the requirements of at least one of the claims of the patent. (In many jurisdictions the scope of the patent may not be limited to what is literally stated in the claims, for example due to the doctrine of equivalents).
An accused infringer has the right to challenge the validity of the patent allegedly being infringed in a countersuit. A patent can be found invalid on grounds described in the relevant patent laws, which vary between countries. Often, the grounds are a subset of requirements for patentability in the relevant country. Although an infringer is generally free to rely on any available ground of invalidity (such as a prior publication, for example), some countries have sanctions to prevent the same validity questions being relitigated. An example is the UK Certificate of contested validity.
Patent licensing agreements are contracts in which the patent owner (the licensor) agrees to grant the licensee the right to make, use, sell, and/or import the claimed invention, usually in return for a royalty or other compensation. It is common for companies engaged in complex technical fields to enter into multiple license agreements associated with the production of a single product. Moreover, it is equally common for competitors in such fields to license patents to each other under cross-licensing agreements in order to share the benefits of using each other's patented inventions.
In most countries, both natural persons and corporate entities may apply for a patent. In the United States, however, only the inventor(s) may apply for a patent although it may be assigned to a corporate entity subsequently and inventors may be required to assign inventions to their employers under an employment contract. In most European countries, ownership of an invention may pass from the inventor to their employer by rule of law if the invention was made in the course of the inventor's normal or specifically assigned employment duties, where an invention might reasonably be expected to result from carrying out those duties, or if the inventor had a special obligation to further the interests of the employer's company.
The inventors, their successors or their assignees become the proprietors of the patent when and if it is granted. If a patent is granted to more than one proprietor, the laws of the country in question and any agreement between the proprietors may affect the extent to which each proprietor can exploit the patent. For example, in some countries, each proprietor may freely license or assign their rights in the patent to another person while the law in other countries prohibits such actions without the permission of the other proprietor(s).
The ability to assign ownership rights increases the liquidity of a patent as property. Inventors can obtain patents and then sell them to third parties. The third parties then own the patents and have the same rights to prevent others from exploiting the claimed inventions, as if they had originally made the inventions themselves.
The grant and enforcement of patents are governed by national laws, and also by international treaties, where those treaties have been given effect in national laws. Patents are granted by national or regional patent offices. A given patent is therefore only useful for protecting an invention in the country in which that patent is granted. In other words, patent law is territorial in nature. When a patent application is published, the invention disclosed in the application becomes prior art and enters the public domain (if not protected by other patents) in countries where a patent applicant does not seek protection, the application thus generally becoming prior art against anyone (including the applicant) who might seek patent protection for the invention in those countries.
Commonly, a nation forms a patent office with responsibility for operating that nation's patent system, within the relevant patent laws. The patent office generally has responsibility for the grant of patents, with infringement being the remit of national courts.
The authority for patent statutes in different countries varies. In the UK, substantive patent law is contained in the Patents Act 1977 as amended. In the United States, the Constitution empowers Congress to make laws to "promote the Progress of Science and useful Arts..." The laws Congress passed are codified in Title 35 of the United States Code and created the United States Patent and Trademark Office.
There is a trend towards global harmonization of patent laws, with the World Trade Organization (WTO) being particularly active in this area. The TRIPs Agreement has been largely successful in providing a forum for nations to agree on an aligned set of patent laws. Conformity with the TRIPs agreement is a requirement of admission to the WTO and so compliance is seen by many nations as important. This has also led to many developing nations, which may historically have developed different laws to aid their development, enforcing patents laws in line with global practice.
In addition, there are international treaty procedures, such as the procedures under the European Patent Convention (EPC) [constituting the European Patent Organisation (EPOrg)], that centralize some portion of the filing and examination procedure. Similar arrangements exist among the member states of ARIPO and OAPI, the analogous treaties among African countries, and the nine CIS member states that have formed the Eurasian Patent Organization. A key international convention relating to patents is the Paris Convention for the Protection of Industrial Property, initially signed in 1883. The Paris Convention sets out a range of basic rules relating to patents, and although the convention does not have direct legal effect in all national jurisdictions, the principles of the convention are incorporated into all notable current patent systems. The most significant aspect of the convention is the provision of the right to claim priority: filing an application in any one member state of the Paris Convention preserves the right for one year to file in any other member state, and receive the benefit of the original filing date. Another key treaty is the Patent Cooperation Treaty (PCT), administered by WIPO and covering more than 140 countries.
Application and prosecution
A patent is requested by filing a written application at the relevant patent office. The person or company filing the application is referred to as "the applicant". The applicant may be the inventor or its assignee. The application contains a description of how to make and use the invention that must provide sufficient detail for a person skilled in the art (i.e., the relevant area of technology) to make and use the invention. In some countries there are requirements for providing specific information such as the usefulness of the invention, the best mode of performing the invention known to the inventor, or the technical problem or problems solved by the invention. Drawings illustrating the invention may also be provided.
The application also includes one or more claims that define what a patent covers or the "scope of protection".
After filing, an application is often referred to as "patent pending". While this term does not confer legal protection, and a patent cannot be enforced until granted, it serves to provide warning to potential infringers that if the patent is issued, they may be liable for damages.
Once filed, a patent application is "prosecuted". A patent examiner reviews the patent application to determine if it meets the patentability requirements of that country. If the application does not comply, objections are communicated to the applicant or their patent agent or attorney through an Office action, to which the applicant may respond. The number of Office actions and responses that may occur vary from country to country, but eventually a final rejection is sent by the patent office, or the patent application is granted, which after the payment of additional fees, leads to an issued, enforceable patent. In some jurisdictions, there are opportunities for third parties to bring an opposition proceeding between grant and issuance, or post-issuance.
Once granted the patent is subject in most countries to renewal fees to keep the patent in force. These fees are generally payable on a yearly basis. Some countries or regional patent offices (e.g. the European Patent Office) also require annual renewal fees to be paid for a patent application before it is granted.
The costs of preparing and filing a patent application, prosecuting it until grant and maintaining the patent vary from one jurisdiction to another, and may also be dependent upon the type and complexity of the invention, and on the type of patent.
The European Patent Office estimated in 2005 that the average cost of obtaining a European patent (via a Euro-direct application, i.e. not based on a PCT application) and maintaining the patent for a 10-year term was around €32,000. Since the London Agreement entered into force on May 1, 2008, this estimation is however no longer up-to-date, since fewer translations are required.
In the United States, in 2000 the cost of obtaining a patent (patent prosecution) was estimated to be from $10,000 to $30,000 per patent. When patent litigation is involved (which in year 1999 happened in about 1,600 cases compared to 153,000 patents issued in the same year), costs increase significantly: while 95% of patent litigation cases are settled out of court, but when the case reaches the court, direct legal costs of patent litigation are on average in the order of a million dollars per case, not including associated business costs.
Alternatives to applying for a patent
A defensive publication is the act of publishing a detailed description of a new invention without patenting it, so as to establish prior art and public identification as the creator/originator of an invention, although a defensive publication can also be anonymous. A defensive publication prevents others from later being able to patent the invention.
A trade secret is the act of not disclosing the methods by which a complex invention works or how a chemical is formulated. Trade secrets are protected by nondisclosure agreements and employment law that prevents reverse engineering and information leaks such as breaches of confidentiality and corporate espionage. Compared to patents, the advantages of trade secrets are that a trade secret is not limited in time (it "continues indefinitely as long as the secret is not revealed to the public", whereas a patent is only in force for a specified time, after which others may freely copy the invention), a trade secret does not imply any registration costs, has an immediate effect, does not require compliance with any formalities, and does not imply any disclosure of the invention to the public. The disadvantages of trade secrets include that "others may be able to legally discover the secret and be thereafter entitled to use it", "others may obtain patent protection for legally discovered secrets", and a trade secret is more difficult to enforce than a patent.
Primary incentives embodied in the patent system include incentives to invent in the first place; to disclose the invention once made; to invest the sums necessary to experiment, produce and market the invention; and to design around and improve upon earlier patents.
- Patents provide incentives for economically efficient research and development (R&D). A study conducted annually by the IPTS shows that the 2,000 largest global companies invested more than 430 billion euros in 2008 in their R&D departments. If the investments can be considered as inputs of R&D, real products and patents are the outputs. Based on these groups, a project named Corporate Invention Board, had measured and analyzed the patent portfolios to produce an original picture of their technological profiles. Supporters of patents argue that without patent protection, R&D spending would be significantly less or eliminated altogether, limiting the possibility of technological advances or breakthroughs. Corporations would be much more conservative about the R&D investments they made, as third parties would be free to exploit any developments. This second justification is closely related to the basic ideas underlying traditional property rights.[specify]
- In accordance with the original definition of the term "patent," patents are intended to facilitate and encourage disclosure of innovations into the public domain for the common good. If inventors did not have the legal protection of patents, in many cases, they might prefer or tend to keep their inventions secret. Awarding patents generally makes the details of new technology publicly available, for exploitation by anyone after the patent expires, or for further improvement by other inventors. Furthermore, when a patent's term has expired, the public record ensures that the patentee's invention is not lost to humanity.[specify]
- In many industries (especially those with high fixed costs and either low marginal costs or low reverse engineering costs — computer processors, and pharmaceuticals for example), once an invention exists, the cost of commercialization (testing, tooling up a factory, developing a market, etc.) is far more than the initial conception cost. (For example, the internal "rule of thumb" at several computer companies in the 1980s was that post-R&D costs were 7-to-1). Unless there is some way to prevent copies from competing at the marginal cost of production, companies don't invest in making the invention a product.[not in citation given]
One effect of modern patent usage is that a small-time inventor can use the exclusive right status to become a licensor. This allows the inventor to accumulate capital from licensing the invention and may allow innovation to occur because he or she may choose not to manage a manufacturing buildup for the invention. Thus the inventor's time and energy can be spent on pure innovation, allowing others to concentrate on manufacturability.
Another effect of modern patent usage is to both enable and incentivize competitors to design around (or to "invent around" according to R S Praveen Raj) the patented invention. This may promote healthy competition among manufacturers, resulting in gradual improvements of the technology base. This may help augment national economies and confer better living standards to the citizens. The 1970 Indian Patent Act allowed the Indian pharmaceutical industry to develop local technological capabilities in this industry. This act transformed India from a bulk importer of pharmaceutical drugs to a leading exporter. The rapid evolution of Indian pharmaceutical industry since the mid-1970s highlights the fact that the design of the patent act was instrumental in building local capabilities even in a developing country like India.
As state-granted monopolies, patents have been criticized as inconsistent with free trade. On that basis, in 1869 the Netherlands abolished patents, and did not reintroduce them until 1912.
Patents have also been criticized for being granted on already-known inventions, with some complaining in the United States that the USPTO fails "to do a serious job of examining patents, thus allowing bad patents to slip through the system." On the other hand, some argue that because of low number of patents going into litigation, increasing quality of patents at patent prosecution stage increases overall legal costs associated with patents, and that current USPTO policy is a reasonable compromise between full trial on examination stage on one hand, and pure registration without examination, on the other hand.
Enforcement of patents – especially patents perceived as being overly broad – by patent trolls, has brought criticism of the patent system, though some commentators suggest that patent trolls are not bad for the patent system at all but instead realign market participant incentives, make patents more liquid, and clear the patent market.
Some have raised ethical objections specifically with respect to pharmaceutical patents and the high prices for medication that they enable their proprietors to charge, which poor people in the developed world, and developing world, cannot afford. Critics also question the rationale that exclusive patent rights and the resulting high prices are required for pharmaceutical companies to recoup the large investments needed for research and development. One study concluded that marketing expenditures for new drugs often doubled the amount that was allocated for research and development. Other critics claim that patents reward and abet misplaced pharmaceutical R&D priorities, which they describe as being directed to creating incremental improved treatments for diseases prevalent in wealthy countries and away from diseases that cause devastation in the developing world.
In response to these criticisms, one review concluded that less than 5 percent of medicines on the World Health Organization's list of essential drugs are under patent. Also, the pharmaceutical industry has contributed US$2 billion for healthcare in developing countries, providing HIV/AIDS drugs at lower cost or even free of charge in certain countries, and has used differential pricing and parallel imports to provide medication to the poor. Other groups are investigating how social inclusion and equitable distribution of research and development findings can be obtained within the existing intellectual property framework, although these efforts have received less exposure.
Some public campaigns for improving access to medicines and genetically modified food have expressed a concern for "preventing the over-reach" of IP protection including patent protection, and "to retain a public balance in property rights". Some economists and scientists and law professors have raised concerns that patents retard technical progress and innovation. Others claim that patents have had no effect on research, based on surveys of scientists.
According to James Bessen, the costs of patent litigation exceed their investment value in all industries except chemistry and pharmaceuticals. For example, in the software industry, litigation costs are twice the investment value.
Proposed alternatives to the patent system
Alternatives have been discussed to address the issue of financial incentivization to replace patents. Mostly, they are related to some form of direct or indirect government funding. One example is the idea of providing "prize money" (from a "prize fund" sponsored by the government) as a substitute for the lost profits associated with abstaining from the monopoly given by a patent. Another approach is to remove the issue of financing development from the private sphere altogether, and to cover the costs with direct government funding.
|Wikiquote has a collection of quotations related to: Patent|
- Glossary of patent law terms
- List of patent-related topics
- List of people associated with patent law
- WIPO Intellectual Property Handbook: Policy, Law and Use. Chapter 2: Fields of Intellectual Property Protection WIPO 2008
- "Patents: Frequently Asked Questions". World Intellectual Property Organization. Retrieved 22 February 2009.
- Article 27.1. of the TRIPs Agreement.
- Article 33 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
- U.S. Patent Activity 1790 to the Present. USPTO .
- Charles Anthon, A Classical Dictionary: Containing An Account Of The Principal Proper Names Mentioned in Ancient Authors, And Intended To Elucidate All The Important Points Connected With The Geography, History, Biography, Mythology, And Fine Arts Of The Greeks And Romans Together With An Account Of Coins, Weights, And Measures, With Tabular Values Of The Same, Harper & Bros, 1841, p. 1273.
- Christine MacLeod, Inventing the Industrial Revolution: The English Patent System, 1660-1800, Cambridge University Press, 2002, ISBN 0-521-89399-2, ISBN 978-0-521-89399-2, p. 11.
- "United Kingdom Patent Applications". nexis.com. Retrieved 29 November 2010.
- Helmut Schippel (2001). Die Anfänge des Erfinderschutzes in Venedig, in: Uta Lindgren (Hrsg.): Europäische Technik im Mittelalter. 800 bis 1400. Tradition und Innovation, 4. Aufl (in German). Berlin: Wolfgang-Pfaller.de: Patentgesetz von Venedig. pp. 539–550. ISBN 3-7861-1748-9
- "History of Copyright". UK Intellectual Property Office. 2006. Retrieved 2007-08-12.
- State of Victoria Library: Patent Resources
- James W. Cortada, "Rise of the knowledge worker, Volume 8 of Resources for the knowledge-based economy", Knowledge Reader Series, Butterworth-Heinemann, 1998, p. 141, ISBN 0-7506-7058-4, ISBN 978-0-7506-7058-6.
- Francoic Velde, Heraldica website, "La Maison Du Roi"
- MarketsAndPatents.com, Nowotarski, Bakos, A Short History of Private Patent Examination, Insurance IP Bulletin October 2009
- Frank D. Prager, "Proposals for the Patent Act of 1790", Journal of the Patent and Trademark Office Society, March 1954, vol XXXVI, No. 3, pp 157 et Seq., citing J. Isore in Revue Historique de Droit Francais, 1937 pp. 117 et Seq.
- Gabriel Galvez-Behar, La République des inventeurs. Propriété et organisation de l'innovation en France, 1791-1922, Presses universitaires de Rennes, 2008, ISBN 2-7535-0695-7, ISBN 978-2-7535-0695-4.
- "A patent is not the grant of a right to make or use or sell. It does not, directly or indirectly, imply any such right. It grants only the right to exclude others. The supposition that a right to make is created by the patent grant is obviously inconsistent with the established distinctions between generic and specific patents, and with the well-known fact that a very considerable portion of the patents granted are in a field covered by a former relatively generic or basic patent, are tributary to such earlier patent, and cannot be practiced unless by license thereunder." – Herman v. Youngstown Car Mfg. Co., 191 F. 579, 584–85, 112 CCA 185 (6th Cir. 1911)
- DLA Piper Rudnick Gray Cary (2005). "Patent Litigation across Europe". cecollect.com.
- "Assignee (Company) Name". Help Page. U.S. Patent and Trademark Office (USPTO). Retrieved 2007-07-25.
- See Section 39 of the UK Patents Act as an example. The laws across Europe vary from country to country but are generally harmonised.
- Article 28.2 TRIPs: "Patent owners shall also have the right to assign, or transfer by succession, the patent and to conclude licensing contracts.".
- Staff, World Intellectual Property Organization (WIPO) FAQ
- United Kingdom law requiring no explicit authority due to the Supremacy of Parliament.
- IP Australia website, What does 'patent pending' mean?, Consulted on August 5, 2009.
- USPTO web site, Patent Marking and "Patent Pending" (Excerpted from General Information Concerning Patents print brochure), Consulted on August 5, 2009.
- UK Intellectual Property Office web site, Display your rights, (under "IPO Home> Types of IP> Patents> Managing your patents> Using and enforcing") Consulted on August 5, 2009.
- With the following assumptions: "18 pages (11 pages description, 3 pages claims, 4 pages drawings), 10 claims, patent validated in 6 countries (Germany, United Kingdom, France, Italy, Spain, Switzerland), excl. in-house preparation costs for the patentee" (the costs relate to European patents granted in 2002/2003), in European Patent Office, The cost of a sample European patent – new estimates, 2005, p. 1.
- Lemley, Mark A., Rational Ignorance at the Patent Office (February 2001). Northwestern University Law Review, Vol. 95, No. 4, 2001. doi:10.2139/ssrn.261400
- Carry a Big Stick
- Bessen, James; Meurer, Michael James (2008). Patent failure: how judges, bureaucrats, and lawyers put innovators at risk. p. 132. ISBN 0-691-13491-X. . Based on an American Intellectual Property Law Association (AIPLA) survey of patent lawyers (2005), and court documents for a sample of 89 court cases where one side was ordered to pay the other side's legal fees.The containing chapter (‘The Costs of Disputes’) also tries to quantify associated business costs.
- Howard T. Markey (chief judge of the United States Court of Customs and Patent Appeals and later of the Court of Appeals for the Federal Circuit), Special Problems in Patent Cases, 66 F.R.D. 529, 1975.
- The 2009 EU Industrial R&D Investment Scoreboard produced by the Institute for Prospective Technological Studies
- Technological profiles for global companies by analysing their patent portfolios
- Stim, Rishand, "Profit from Your Idea: How to Make Smart Licensing Decisions", ISBN 1-4133-0450-8 (2006)
- Kim, Linsui (2002). "Technology Transfer and Intellectual Property Rights: Lessons from Korea's Experience". Unctad/ictsd. UNCTAD/ICTSD Working Paper.
- Kumar, Nagesh (2002). "Intellectual Property Rights, Technology, and Economic Development: Experience of East Asian Countries". RIS Discussion Paper 25.
- Chang, Ha-Joon. "Kicking Away the Ladder: How the Economic and Intellectual Histories of Capitalism Have Been Re-Written to Justify Neo-Liberal Capitalism". Post-Autistic Economics Review. 4 September 2002: Issue 15, Article 3. Retrieved on 8 October 2008.
- Barker, David G. (2005). "Troll or no Troll? Policing Patent Usage with an Open Post-grant Review". Duke Law & Technology Review 9 (11). Retrieved 9 June 2013.
- Blumberg, Alex; Sydell, Laura (May 31, 2013). "When Patents Attack... Part Two!". This American Life (Podcast). Chicago Public Media. http://www.thisamericanlife.org/radio-archives/episode/496/when-patents-attack-part-two. Retrieved June 9, 2013.
- James F. McDonough III (2006) The Myth of the Patent Troll accessed 2010-01-17
- Banta D.H. (2001) Worldwide Interest in Global Access to Drugs Journal of the American Medical Association 285 (22): 2844–46
- Ferreira L. (2002) Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational Pharmaceutical Corporations Fordham Law Review 71(3):1133–79
- Barton J.H. and Emanuel, E.J. (2005) The Patents-Based Pharmaceutical Development Process: Rationale, Problems and Potential Reforms Journal of the American Medical Association 294(16): 2075–82
- Schaaber, Jörg (2010/11). "Misguided research". inwent.org. Retrieved 29 November 2010.
- Ghafele R (2008) Perceptions of Intellectual Property: A Review London: Intellectual Property Institute
- Susan K Sell (2003), Private Power, Public Law: The Globalization of Intellectual Property Rights, Cambridge, 2003 (Cambridge University Press: Cambridge Studies in International Relations: 88; quoted from page 179, see also page 5.
- Dutfield, Graham (2003). Intellectual Property Rights and the Life Science Industries: A Twentieth Century History. ISBN 9780754621119.
- Levine, David; Michele Boldrin (2008-09-07). Against intellectual monopoly. Cambridge University Press. ISBN 978-0-521-87928-6.
- J. M. Pearce, Make nanotechnology research open-source, Nature 491, pp. 519–521(2012). DOI: 10.1038/491519a
- Science Progress Blog
- Bessen, James, 2008. "The value of U.S. patents by owner and patent characteristics," Research Policy, Elsevier, vol. 37(5), pages 932-945, June.
- Stiglitz, Joseph. Project Syndicate, 2007. project-syndicate.org
- Baker, Dean. "The Reform of Intellectual Property". post-autistic economics review, issue no. 32, 5 July 2005, article 1, Paecon.net
|Wikimedia Commons has media related to Patents.|
|Look up patent in Wiktionary, the free dictionary.|
- Directory of Intellectual Property Offices, maintained by World Intellectual Property Organization (WIPO)
- Useful links, maintained by the European Patent Office
- OECD Patent statistics
- Henderson, David R. (2002). "Patents". Concise Encyclopedia of Economics (1st ed.). Library of Economics and Liberty. OCLC 317650570, 50016270 and 163149563
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 動脈管開存症のマネージメント management of patent ductus arteriosus
- 2. 早産児における動脈管開存症の病態生理、臨床症状、および診断 pathophysiology clinical manifestations and diagnosis of patent ductus arteriosus in premature infants
- 3. 動脈管開存症の臨床症状および診断 clinical manifestations and diagnosis of patent ductus arteriosus
- 4. 卵円孔開存 patent foramen ovale
- 5. 早産児における動脈管開存症のマネージメント management of patent ductus arteriosus in premature infants
- Usefulness of intracardiac echocardiography with a mechanical probe for catheter-based interventions: A 10-year prospective registry.
- Rigatelli G1, Dell'Avvocata F, Giordan M, Viceconte N, Osanna RA, Braggion G, Aggio S, Cardaioli P, Chen JP.
- Journal of clinical ultrasound : JCU.J Clin Ultrasound.2014 Nov 12;42(9):534-43. doi: 10.1002/jcu.22177. Epub 2014 Jun 4.
- BACKGROUND: The clinical outcome benefit of intracardiac echocardiography (ICE) with a mechanical probe during congenital heart disease interventions has not been fully investigated. We reported the long-term results of a prospective registry of interatrial shunt closure guided by mechanical ICE.MET
- PMID 24898198
- Perfusion index variability in preterm infants treated with two different natural surfactants for respiratory distress syndrome.
- Karadag N, Dilli D, Zenciroglu A, Aydin B, Beken S, Okumus N.
- American journal of perinatology.Am J Perinatol.2014 Nov;31(11):1015-22. doi: 10.1055/s-0034-1370344. Epub 2014 Feb 24.
- Objective The objective of this study was to compare the perfusion index (PI) variability in premature infants with respiratory distress syndrome (RDS) following administration of two different natural surfactant preparations. Study design This was a prospective study on 92 preterm infants with
- PMID 24566756
- Independent predictors of human milk receipt at neonatal intensive care unit discharge.
- Brownell EA1, Lussier MM1, Hagadorn JI1, McGrath JM2, Marinelli KA1, Herson VC1.
- American journal of perinatology.Am J Perinatol.2014 Nov;31(10):891-8. doi: 10.1055/s-0033-1363500. Epub 2013 Dec 17.
- Objective The aim of this study is to construct a predictive model for very low birth weight (VLBW) infants' receipt of mother's own milk within 24 hours before neonatal intensive care unit (NICU) discharge. Study Design Vermont Oxford Network (VON) clinical data were analyzed retrospectively fo
- PMID 24347254
- The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon Cancer Patients.
- Vogelaar FJ1, Reimers MS, van der Linden RL, van der Linden JC, Smit VT, Lips DJ, van de Velde CJ, Bosscha K.
- Annals of surgical oncology.Ann Surg Oncol.2014 Nov;21(12):3924-30. doi: 10.1245/s10434-014-3820-5. Epub 2014 Jun 10.
- BACKGROUND: Lymph node status in colon cancer is critical for prognosis estimation and treatment allocation. The purpose of this study was to compare the performance of one-step nucleic acid amplification (OSNA) through detection of cytokeratin 19 mRNA levels with routine pathological examination (R
- PMID 24912612
- 鈴木 克典,湯川 高志
- 情報処理学会論文誌 54(1), 414-422, 2013-01-15
- 企業が技術戦略を策定する際,技術動向を調査・視覚化してその方針決定に役立てる.このような調査に有益なツールの1つとして特許マップがあり,多くの場合,この作成には特許文書に付与されている国際特許分類(IPC)コードが利用される.この特許マップに学術論文の情報を追加することができれば,より有益なツールになると考えられるが,現在学術論文はIPCに基づいた分類が成されておらず特定分野の網羅的な調査には大き …
- NAID 110009511465
- 座談会 特許事務所における人材育成 (特集 知財における人材育成)
- 恩田 博宣,石川 泰男,龍華 明裕 [他]
- パテント 66(1), 8-30, 2013-01
- NAID 40019543588
- 知財管理 = Intellectual property management 63(1), 133-136, 2013-01
- NAID 40019541541
- 松本 司
- 知財管理 = Intellectual property management 63(1), 79-89, 2013-01
- NAID 40019540950
- 弁理士は、知的財産の創造から活用までをサポートします。 ... 国内外の知的財産権に関するトピックスを発信するため、月刊「パテント」を発行しており、会員ならびに全国の関係機関や団体に送付しています。
- Commencement of the Patent Prosecution Highway Program between the JPO and the Industrial Property Office of the Czech Republic (Press Release on the METI Web Site) [Last updated March 11, 2015] JPO Compiled a ...
|拡張検索||「patentee」「unpatented」「letters patent」「patently」「patent office」|